The GLP-1 Clinic Operations Playbook: Intake, Titration, and Retention
A mobile-first operations playbook for GLP-1 and metabolic-health clinics: intake screening, titration cadence, side-effect triage, and the retention math that decides whether month six happens.
Running a GLP-1 or metabolic-health clinic is less about the prescription and more about the twelve months around it. This playbook walks through the four workflows that decide whether a patient reaches month six with durable results — intake screening, titration cadence, side-effect triage, and retention.
Intake screening that actually filters
The intake questionnaire should surface personal or family history of medullary thyroid carcinoma or MEN2 (label contraindication for GLP-1 receptor agonists), prior pancreatitis, gastroparesis, active or recent eating disorder, pregnancy plans in the next 60 days, and current insulin or sulfonylurea use (hypoglycemia risk). A 10-question form catches almost all of it.
Screen for the co-morbidities that change the risk-benefit before the visit: MASLD/MASH, obstructive sleep apnea, ASCVD, type 2 diabetes, PCOS. These are indications, not contraindications, but they change the follow-up cadence and the labs you order at week four.
Titration cadence and the nausea window
The label titration schedule (four-week steps for semaglutide, four-week steps for tirzepatide) is a ceiling, not a floor. Patients who plateau tolerably at a lower dose do better on retention than patients pushed to label maximum through active nausea. Give the clinic team explicit authority to hold a dose for a cycle without a physician touch.
The nausea window (weeks 1–3 after each step-up) is where most drop-off happens. A short pre-emptive text — hydration, small meals, expected timeline — cuts the call volume and the churn.
Side-effect triage and the same-day line
Every GLP-1 program needs a same-day side-effect phone line or secure-message queue with defined escalation: standard GI symptoms are handled by MA/RN; severe abdominal pain, persistent vomiting, or signs of pancreatitis go same-day to a clinician; anything with gallbladder radiation or jaundice goes ED. Publish the tree; do not run it out of the physician's inbox.
See the companion post on the primary care side-effect decision tree for the specific escalation criteria.
Retention math: month-3 and month-6 are the KPIs
Clinics that measure only weight-loss percentage optimize for the wrong number. Month-3 retention (are they still on therapy?) and month-6 retention (are they still on therapy AND coming to visits?) predict twelve-month outcomes far better. Target month-3 ≥ 75%, month-6 ≥ 60% as operational floors; below those, the operations problem is upstream of the drug.
Every unfilled refill is a coaching opportunity, not a chart-close. Build the workflow to reach out on day 5 of a late refill, not on day 30.
Staffing shape and reimbursement
A well-run GLP-1 clinic at 200 active patients per prescriber typically staffs at 1 prescriber + 1 RN/pharmacist + 1 MA + 1 patient coordinator. Group visits (billable in most payer mixes under 99XXX codes) can double the effective panel without diluting quality. Nutrition and behavioral counseling are the highest-leverage add-ons — and often independently reimbursable.
Frequently asked questions
- What is the biggest driver of GLP-1 drop-off in the first 90 days?
- Untreated or unacknowledged GI side effects, primarily nausea and constipation. Same-day access to a clinical team member and a proactive touch during each titration step cut early drop-off substantially.
- How many patients can one prescriber manage in a GLP-1 clinic?
- With RN or pharmacist support and structured group visits, a single prescriber can manage 200–300 active patients while maintaining month-6 retention above 60%.
- Are GLP-1s appropriate for patients without diabetes?
- Yes — semaglutide (Wegovy) and tirzepatide (Zepbound) are FDA-approved for chronic weight management in adults with obesity or overweight plus a weight-related comorbidity. Payer coverage varies.
- Do patients need to stay on GLP-1 medication indefinitely?
- Current evidence shows weight regain in most patients within 12 months of discontinuation. Long-term therapy — with periodic dose reassessment — is the working assumption for most patients, similar to other chronic disease medications.